Loss of PTEN expression or PTEN mutations were associated with the TNBC subtype more frequently than with HER2- or ER/PR-positive subtypes and have been correlated with breast cancer progression, brain relapse and metastasis [60]. This evidence concerns the gene ERBB2 and breast carcinoma.